Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
LAIYANG, China, Feb. 22 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that the Company will host a conference call at 8:30 a.m. Eastern on Friday, February 26, 2010 to discuss financial results for the second quarter ended December 31, 2009 of its fiscal year 2010.
The conference call will include Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, of Jiangbo.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (877) 700-5838. International callers should dial +1 (706) 758 - 5465. The Conference ID for this call is 58049438.
If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Friday, February 26, 2010 at 9:30 a.m. Eastern Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291. Conference ID is 58049438.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com ).
For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-727-8435 Email: [email protected] Web: http://www.jiangbopharma.com CCG Investor Relations, Inc. Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: [email protected] Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: [email protected]
SOURCE Jiangbo Pharmaceuticals, Inc.
Share this article